Discover the side effects of mosquirix.
Although death rates, thankfully, have gone down over the past decade, more than 400,000 people, mainly children, still died from malaria in 2019. Given how severe malaria can be, this vaccine is welcome news
Until now, a preventive vaccine against malaria hasn’t been available.
Researchers have realized the cause of malaria since 1880 — for more than 140 years — but a vaccine has been tough to develop.
Mosquirix assists the body makes antibodies that recognize malaria parasites. Antibodies are proteins that improve our immune cells (called white blood cells) fight germs like parasites.
When malaria parasites penetrate the body, they travel through the bloodstream and go to the liver. In the liver, these parasites can get stronger and multiply. After a child is fully vaccinated with four doses, Mosquirix works by halting the parasites’ growth in the liver.
Mosquirix side effects are relatively similar to other vaccines. The most common side effects are pain and swelling at the injection site and fever.
Other side effects may include:
•Appetite that’s less than normal
Reasonable medical treatment and supervision should always be readily available in case of an anaphylactic event pursuing the administration of the vaccine.
It is a good clinical strategy to precede vaccination by a review of the medical history (especially about previous vaccination and feasible occurrence of undesirable effects) and a clinical examination.
As with other vaccines, vaccination with Mosquirix should be postponed in subjects suffering from an acute serious febrile illness.
The existence of a minor infection, such as a cold, should not result in the deferral of vaccination.
A history of febrile seizures or a family history of convulsions does not constitute a contraindication for the use of Mosquirix.
Vaccinees, particularly those with a history of febrile convulsions, should be closely followed up as vaccine-related fever may occur after vaccination.
In case of fever, antipyretic measures should be initiated according to local guidelines.
Fever may follow each dose of Mosquirix. Clinical data produced with other paediatric vaccines suggest that the prophylactic use of paracetamol might reduce the immune response to vaccine antigens.
The clinical pertinence of this observation remains unknown.
In absence of clinical data with Mosquirix, the routine use of prophylactic antipyretic medicinal products before vaccination is therefore not recommended.
Do not administer the vaccine intravascularly, intradermally or subcutaneously.
As with other vaccines administered intramuscularly, Mosquirix should be given with warning to individuals with thrombocytopenia or any coagulation disorder since bleeding may arise following an intramuscular administration to these subjects.
The potential risk of apnoea and the need for respiratory monitoring for 48 to 72 h should be contemplated when administering the first three doses to very preterm infants (born ≤ 28 weeks of gestation) who stay hospitalized at the time of vaccination and particularly for those with a previous history of respiratory immaturity.
To enhance the traceability of biological medicinal products, the name and the batch number of the administered product should be recorded.
Discover the 14 incredible health benefits of boiled apple water and side effects. Some people… Read More